To date, research efforts investigating sequential therapy in HCC after sorafenib failure have proven this from prospective clinical studies including TKIs regorafenib and cabozantinib, and VEGFR-2 inhibitor ramucirumab. Here, KDR is linked to hepatocellular carcinoma.